Oppenheimer Upgrades Inspire Medical to Outperform with $85 Target After Q2 Beat
Company raises 2026 guidance and launches cost-cutting plan.
/ 6 items
#INSP↓
CMS Clears Path for Hypoglossal Nerve Stimulation: New Codes Signal Reimbursement Clarity for Inspire and Nyxoah
CMS resolves hypoglossal nerve stimulation reimbursement confusion by adding 6 new HCPCS codes (effective Jan 1, 2026), viewed as positive for Inspire & Nyxoah.
Inspire Medical Stock Falls After Medicare Reimbursement Correction
Inspire Medical shares dropped after Medicare corrected a reimbursement error, prompting Oppenheimer to downgrade the stock while Evercore remained optimistic.
Inspire Medical Stock Drops on Medicare Billing Confusion, Analysts Stay Positive
Inspire Medical shares fall after Medicare billing code confusion, but major analysts remain confident in long-term growth.
Morgan Stanley Issues Key Rating Changes Across MedTech and Healthcare Stocks
Morgan Stanley updates ratings for Inspire Medical, DexCom, and Bausch + Lomb, highlighting slowing growth, improving operations, and strong long-term pipelines.
Inspire Medical Soars 29% on Medicare Payment Boost
Inspire Medical Systems stock jumps after CMS approves major Medicare payment increase for sleep apnea procedures, effective 2026. Stifel upgrades to Buy.